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Abstract
Circulating cell-free DNA (cfDNA) refers to extracellular DNA present in body fluid that 
may be derived from both normal and diseased cells. The concentration, integrity, genetic, 
and epigenetic alternations in the cfDNA may suggest pathological conditions of the body, 
such as inflammation, autoimmune diseases, stress, or even malignancies. cfDNA from 
patients with malignancies contains variants as those in the tumor tissue cells, thus allow-
ing noninvasive assessment of tumor in real time. The clinical detection of cfDNA is one 
major application of liquid biopsy and has great application value in the early diagnosis of 
clinical tumors, real-time progression monitoring, curative effect observation and evalu-
ation, prognosis assessment, and metastasis risk analysis. This chapter summarizes the 
origin of cell-free DNA and its important clinical applications as a noninvasive biomarker.
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1. Introduction
Liquid biopsy, a term relative to tissue biopsy, is a technical way to analyze the nonsolid bio-
logical tissue by detection of cells and free DNA that enter body fluids. Liquid biopsy refers to 
the real-time monitoring of the dynamic alterations of disease by detecting circulating tumor 
cells (CTCs), circulating cell-free DNA (cfDNA), exosomes and so on. This technique has great 
application value as a tool for disease early diagnosis, real-time progression monitoring, cura-
tive effect observation and evaluation, prognosis assessment, and metastasis risk analysis, 
with the added benefit of being noninvasive and flexible for repeat tumor sampling [1–3].
Circulating cell-free DNA (cfDNA) is released as single-stranded DNA and double-stranded 
DNA into body fluids, including the blood [4], sputum [5], urine [6], cerebrospinal fluid [7], or 
ascites [8] from apoptotic and necrotic cells [9]. cfDNA was first identified by Mandel and Metais 
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
in the human blood in 1948 [10]. In 1977, Leon discovered that circulating cell-free DNA was 
also existed in cancer patients [11]. In 1997, Lo et al. found the presence of a small percentage of 
cfDNA originating from the fetus in the maternal plasma and serum. Then cfDNA was first used 
for noninvasive prenatal testing, including fetal sex assessment which can identify sex for fetus 
[12], RhD blood group genotyping, detection of chromosomal aneuploidy, and fetal-related 
diseases. These diseases include systemic lupus erythematosus (SLE), an autoimmune disease 
involving multiple systems, multiple organs, and multiple autoantibodies [13], and monogenic 
diseases, such as β-globin gene and HBB gene [14]. At present, as an important aspect of liquid 
biopsy, the detection of circulating cell-free DNA displays its irreplaceable advantages in clinic, 
including simpleness and accessibility. Compared with the solid biopsy, the liquid biopsy by 
detection of cfDNA is noninvasive and easily repeated. The detection of cfDNA as a clinic marker 
has amounts of advantages. The intra-abnormalities can be detected in cfDNA at an earlier time, 
thus enabling early diagnosis of disease. And the detection of cfDNA makes repeated sampling 
possible for the monitoring of disease progression, drug response, and prognostic tracking.
2. Clinical applications of circulating cell-free DNA
The concentration, integrity, genetic, and epigenetic alternations in the cfDNA may suggest 
pathological conditions of the body, such as inflammation, autoimmune diseases, stress, or 
even malignancies. Different disease-associated molecular characteristics can be detected as 
the indicators of pathological conditions in the plasma of patients, including the total level and 
fragment, copy-number aberrations [15–18], methylation changes [19–21], single-nucleotide 
mutations [16, 22–25], cancer-derived viral sequences [26, 27], and chromosomal rearrange-
ments [28, 29]. cfDNA from patients with malignancies (cell-free tumor DNA, ctDNA) contains 
variants as those in the tumor tissue cells, thus allowing noninvasive assessment of tumor in 
real time. ctDNA is a very promising tumor biomarker for cancer diagnosis and monitoring, 
prognosis assessment, and personalized medication guidance compared with conventional 
serum markers.
2.1. The size of cfDNA
The length of cfDNA from patients differs from that of healthy groups, which may suggest 
some kinds of physiological or pathological conditions, including pregnancy, cancer, liver/
bone marrow transplantation, SLE, and many other clinical scenarios such as stroke, auto-
immune disorders, and myocardial infarction [30–37]. The length of cfDNA was previously 
identified by gel electrophoresis and electron microscopy (EM) in 1998. Giacona et al. found 
that most abundant cfDNA fragments from pancreatic cancer patients displayed stronger 
ladder patterns compared with that from healthy controls, which was equivalent to whole-
number multiples (1–5×) of nucleosomal DNA (185–200 bp). The average strand length distri-
butions of DNA (DNA-SL) in pancreatic cancer patients were also obviously shorter (231 nm; 
median, 185 nm) than average plasma DNA-SL in controls (311 nm; median, 273 nm). There 
were more excess of short DNA at approximately 63, approximately 126, approximately 189, 
approximately 252, and approximately 315 nm, corresponding to small multiples of lengths 
Liquid Biopsy38
associated with nucleosomes, in the pancreatic cancer patient plasma than in the plasma of 
healthy control [38]. The molecular size-distribution profiles of plasma DNA in systemic 
lupus erythematosus (SLE) patients exhibited a significantly increased proportion of short 
DNA fragments [22]. Jiang et al. found that the plasma DNA molecules from hepatocellular 
carcinoma patients were aberrantly short or long through massively parallel sequencing and 
the aberrantly short ones preferentially carried tumor-associated copy-number aberrations 
[23]. The study now confirms that the overall size of cfDNA was approximately 166 or 143 bp 
or even shorter with a periodicity of 10 bp [37]. The size distributions of cfDNA prominent 
peak were focused in 166 bp for hepatocellular carcinoma (HCC) patients and hepatitis B 
virus (HBV) carriers [39]. The size of cfDNA fragment was different from the systemic lupus 
erythematosus patients that the height of the 166 bp peak was reduced and has smaller peaks 
and healthy individuals [40]. These abundant cfDNA molecules were most likely gener-
ated from apoptosis cells accompanied with certain enzymatic cleavage processes shaped 
by nucleosome-associated DNA packing [34, 40–43]. With the technology development and 
refinement for the determination of cfDNA fragment size, cfDNA fragment size and its distri-
bution provide important information associated with pathological conditions and display to 
be a promising indicator for clinical diagnosis.
2.2. cfDNA concentration
The concentration or level of cfDNA could change with different physiological conditions. 
The study described the concentration of cfDNA in patients with non-small cell lung cancer 
(NSCLC) was higher than healthy controls, and the average level was 95.67 and 59.60 ng/μl, 
respectively [44]. The concentrations of overall cfDNA in cancer patients have a significant 
increase with a wide range (hundreds to thousands ng/ml in the blood) compared with 
in the healthy controls (a relative level of 30 ng/ml) [45–48]. The level of cfDNA in cancer 
patients, such as in ovarian cancer, colorectal cancer, and pancreatic cancer, is significantly 
associated with the cancer-specific survival and can be used as an independent predictor 
for death [22, 46, 47]. The study found preoperative cell-free DNA levels are significantly 
elevated in patients with epithelial ovarian carcinoma (EOC), and the cell-free DNA level is a 
potential predictor for clinical outcome in patients with ovarian cancer. For colorectal cancer 
patients, the cfDNA level is correlated with a shorter survival and may be a biomarker for 
survival when it is above 1000 ng/ml [47]. The level of cfDNA is the highest in pancreatic 
ductal adenocarcinoma compared with pancreatic neuroendocrine tumor and chronic pan-
creatitis using Alu repeat amplicon [1]. The cfDNA level also can be used as a marker of 
cellular trauma and inflammation from anesthesia and surgery in clinic. The concentration 
of cfDNA displayed significant differences and fluctuation pattern during serial periopera-
tive process in donors and recipients undergoing living donor liver transplantation (LDLT). 
The cfDNA concentration is higher in recipients than in donor undergoing living donor liver 
transplantation and is an indicative marker for liver injury. The cfDNA level fluctuated from 
a baseline 37.62 ng/ml to a relative high level of 94.72 ng/ml in recipient who developed 
postoperative sepsis [49]. In the study of lung cancer, the patients with high baseline cfDNA 





2.3. cfDNA genetic variations
Cell-free DNA generates from apoptosis or necrosis cells and contains the same genetic varia-
tions with intra-tissues. cfDNA is widely used as a genetic biomarker for disease diagnosis and 
monitoring by detection of the copy-number variations, SNPs, and mutation occurred in cfDNA.
2.3.1. Copy-number variations of cfDNA
Copy-number variations (CNV) are always associated with the occurrence of complex disor-
ders. The CNV of urine cfDNA in advanced prostate cancer patients is significantly associated 
with tumor burden, and the CNV change after stage-specific therapies reflected disease pro-
gression status and overall survival [51]. Copy-number variations of HLA-DRB5 in 135 sys-
temic lupus erythematosus (SLE) patients were higher than that in 219 healthy controls and 
were associated with the risk of SLE. The copy-number at 6p21.32 is aberrant in the majority 
of SLE patients [52]. In the plasma of neuroblastoma patients, the copy-number alterations of 
cfDNA displayed concordant high patterns and can be used as a cost-effective, noninvasive, 
rapid, robust, and sensitive biomarker for neuroblastoma prognosis [53].
2.3.2. Mutation of cfDNA
Mutation is a widespread phenomenon in biology, the effect of which is permanent alteration 
of nucleotide sequence. Mutations play a vital role in both normal and abnormal biological 
processes, such as evolution and cancer. Many studies display that the mutation detection in 
cfDNA will enable noninvasive tumor diagnosis and monitoring with higher sensitivity and 
specificity in advance [54, 55]. Many patients with advanced lung cancers that are resistant to 
AZD9291 therapy carried EGFR C797S mutation in cfDNA [56]. EGFR mutations in cfDNA were 
significantly associated with overall survival (OS), progression-free survival (PFS), and response 
to therapy in the EURTAC trial. The EGFR L858R mutations in cfDNA proved to be a novel 
prognostic marker [57]. In melanoma, BRAF mutation in cfDNA can be detected earlier than 
primary lesion [58]. KRAS mutation in cfDNA for pancreatic ductal adenocarcinoma (PDAC) 
provided a new diagnostic marker and could optimize therapeutic strategies for patients [59].
2.3.3. SNP of cfDNA
Single-nucleotide polymorphism is a variation in a single nucleotide occurring in the genome 
at a specific position. Detection of SNP in circulating cell-free DNA has been widely used 
in prenatal screening. The detection of SNP located in SRY gene or TSPY gene in Y chromo-
some proved to be a highly accurate and clinically applicable noninvasive prenatal diagnosis 
(NIPD) marker for fetal gender determination [60–62]. The study reported first trimester con-
tingent screening used nuchal translucency and cell-free DNA, the latter has higher detection 
rate that is up to 98% for trisomy 21, but noninvasive prenatal testing will not be cost-effective 
associated with traditional [63, 64].
2.4. cfDNA methylation as epigenetic biomarker
Epigenetic modifications are heritable molecular events that affect gene expression without 
changing DNA sequences, including DNA methylation, histone modification, and so on. 
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They are stable through cell division. DNA methylation refers to the addition of methyl group 
to cytosine residues in DNA sequence, and it is the best-studied epigenetic event [65, 66]. The 
quantitative DNA methylation analysis of tumor-derived cell lines was conducted in 1999 
for the first time, and the possibility of using them as noninvasive biomarkers for cancer was 
examined [21, 67, 68]. Various studies were performed to detect cfDNA to assess the perfor-
mance of cfDNA methylation as a biomarker [64].
The level of cfDNA methylation for GSTP1 and APC in the castration-resistant prostate cancer 
patients could be used as a marker reflecting treatment response and prognosis [69]. The 
BRMS1 promotor in cfDNA could provide prognostic information from the plasma of NSCLC 
and highly methylated from advanced NSCLC patients [70]. cfDNA epigenetic pattern can be 
used as an early diagnostic marker for breast cancer [71].
3. Conclusion
At present, cfDNA has been used as an independent marker for prenatal screening and also 
has great applicable value in the disease prognosis and monitoring, particularly in cancer. 
When the concentration of cfDNA is above a baseline 30 ng/ml and is closed to hundreds or 
even thousands ng/ml, or/and when the size of cfDNA is obviously short and displays ladder 
pattern, or/and when vital genetic and epigenetic mutations are reported in cfDNA, patients 
should be recommended for further examination. The appearance of cfDNA conforms to the 
current trend of precision medicine in the disease and achieves accurate diagnosis and pre-
cise treatment. However, there are many challenges in the real clinic applications. Firstly, the 
detected method is not uniform and the standardization process is lacking [72]. Secondly, the 
level of cfDNA can be too low, so the detection technology needs to be improved to increase 
the sensitivity and specificity [73, 74].
The study of cfDNA is still in its infancy, and a lot of in-depth research is needed to further 
confirm its clinical application value.
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